Pregabalin Capsule
Product Images NDC 58118-1464

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 58118-1464). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 100mg Capsule 30ct Blister Card (Prega 100mg 90s A)

This is a description of a medication package containing Pregabalin 100mg capsules. The package details include NDC numbers, quantity, manufacturer information (Ascend Laboratories, LLC), expiration date (2027 Feb), batch number (SAMPLE123), and location of the manufacturer (Parsippany, NJ, USA). The text also includes references to clinical solutions and the distributor (CiriclSutor W LG).*

FDA Label Image

Pregabalin 150mg Capsule 30ct Blister Card (Prega 150mg 90s A)

FDA Label Image

Pregabalin 200mg Capsule 30ct Blister Card (Prega 200mg 500s A)

FDA Label Image

Pregabalin 50mg Capsule 30ct Blister Card (Prega 50mg 500s A)

FDA Label Image

Pregabalin 75mg Capsule 30ct Blister Card (Pregabalin 75 90 1)

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This text seems to discuss a formula for estimating Creatinine Clearance (CLCr) using the patient's age, weight, and serum creatinine level. The calculation involves multiplying the patient's age by weight and dividing it by 72 times the serum creatinine level in mg/dL. It also notes that the CLCr value should be greater than 0.85 for female patients.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

This text appears to be a statistical comparison between various studies evaluating the effectiveness of different doses of a drug compared to a placebo. The text mentions different dosages (50mg/day, 150mg/day, 300mg/day, 600mg/day) and presents some percentage values related to the studies. The results indicate statistical significance compared to the placebo, although specific details regarding the drug and its effects are not fully clear.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

The text provides data on the percentage of patients showing improvement in pain after taking medication known as Pregatalin three times a day, compared to a placebo. The numbers suggest a significant improvement in pain management with Pregatalin treatment.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

This text appears to show the percentage of patients improved with different doses of Pregabalin. It includes information such as the daily dose of Pregabalin administered and the percentage of improvement in pain from baseline for each dosage. The data indicates the effectiveness of Pregabalin in managing pain based on different dosage levels.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.